CHRO Chromocell Therapeutics
- 1.020
- +0.269+35.78%
- 1.090
- +0.070+6.86%
Chromocell Therapeutics News
Chromocell Therapeutics | DEF 14A: Definitive information statements
Chromocell Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Malamut Richard
Chromocell Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Francis Knuettel II
Chromocell Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Francis Knuettel II
Chromocell Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Chromocell Therapeutics | 424B3: Prospectus
Chromocell Therapeutics | 424B3: Prospectus
Chromocell Therapeutics | 10-Q: Q2 2024 Earnings Report
Chromocell Therapeutics | 8-K: Current report
Chromocell Therapeutics | EFFECT: Others
Chromocell Therapeutics | 424B3: Prospectus
Chromocell Therapeutics | D: Filing D
Chromocell Therapeutics | D: Filing D
Chromocell Therapeutics | CORRESP: CORRESP
Chromocell Therapeutics | UPLOAD: Others
Chromocell Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933
Chromocell Therapeutics | 424B3: Prospectus
Chromocell Therapeutics | 424B3: Prospectus
Chromocell Therapeutics | 8-K: Current report
Chromocell Therapeutics | 3/A: Initial statement of beneficial ownership of securities (Amendment)-Officer Francis Knuettel II
Analysis
Price Target
No Data
No Data